江苏恒瑞医药股份有限公司第九届董事会第二十一次会议决议公告

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. held its 21st meeting of the 9th Board of Directors on December 10, 2025, where significant resolutions were passed, including amendments to the company's articles of association and the convening of the second extraordinary general meeting of shareholders in 2025 [1][2]. Group 1: Board Meeting Resolutions - The Board approved the amendment to the articles of association with unanimous support (11 votes in favor, 0 against, 0 abstentions) [1]. - The Board also approved the convening of the second extraordinary general meeting of shareholders in 2025, with the same unanimous support [1]. Group 2: Shareholders' Meeting Details - The second extraordinary general meeting of shareholders is scheduled for December 31, 2025, at 14:30 [3]. - The meeting will utilize a combination of on-site and online voting methods, with the online voting system provided by the Shanghai Stock Exchange [3][4]. - Voting will be available on the day of the meeting from 9:15 to 15:00, with specific time slots for different voting methods [4]. Group 3: Voting Procedures - Shareholders can vote through the Shanghai Stock Exchange's online voting system, either via trading system platforms or internet platforms [5][6]. - Shareholders holding multiple accounts can aggregate their voting rights across all accounts, but must ensure that votes do not exceed their total eligible votes [6]. Group 4: Meeting Attendance - Shareholders registered by the close of trading on the registration date are entitled to attend the meeting, and they may appoint proxies to represent them [7][8]. - The registration period for attending the meeting is set for December 23, 2025, from 9:30 to 16:00 [10]. Group 5: Other Matters - The company will provide a reminder service for shareholders to facilitate attendance and voting, utilizing smart messaging services [12]. - Contact information for the company's securities affairs department is provided for any inquiries related to the meeting [12].